Understanding how PARP2 affects RNA structures in blood disorders
Official title: Elucidating molecular mechanisms of PARP2 at R loops in myelodysplastic syndromes
Funded at University of Minnesota · NIH-11070505 · Data updated 2026-11-12
This study is looking at how a protein called PARP2 affects certain RNA structures in people with myelodysplastic syndromes (MDS), a blood disorder, to find new ways to help improve treatment options for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $35,323 |
| NIH project number | 1F31HL178160-01 |
| Project ID | NIH-11070505 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with myelodysplastic syndromes, particularly those with mutations in RNA splicing factor genes.
✕Less likely to help
Patients without myelodysplastic syndromes or those with different underlying causes of blood disorders may not benefit from this research.
What this research studies
This research investigates the role of PARP2 in regulating R loops, which are important RNA structures, in patients with myelodysplastic syndromes (MDS). MDS is a serious blood disorder that can lead to acute myeloid leukemia, and the study focuses on how mutations in RNA splicing factors affect disease progression. By exploring the molecular mechanisms involved, the research aims to identify potential therapeutic targets that could improve patient outcomes. The approach includes laboratory experiments to analyze the interactions between PARP2 and R loops in cells with specific genetic mutations.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve survival and quality of life for patients with myelodysplastic syndromes.
How similar studies have gone: Previous research has shown promising results in targeting similar molecular mechanisms in blood disorders, indicating potential for success in this area.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Mcmahon, Matthew Charles — University of Minnesota
- Study coordinator: Mcmahon, Matthew Charles
Related research
Other NIH-funded projects on the same topics.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Whole-genome sequencing to refine risk in myelodysplastic syndromes (MDS) for older adults
This project uses clinical whole-genome sequencing to improve genetic profiling and better predict how MDS will progress in older patients.
-
Targeting gasdermin D to treat myelodysplastic syndromes in people with bone marrow inflammation
A research project aims to find new ways to treat myelodysplastic syndromes by blocking a protein (gasdermin D) involved in harmful bone marrow inflammation.
-
Understanding why some MDS patients relapse after a stem cell transplant
A study of patients with myelodysplastic syndromes after stem cell transplant to learn the cellular changes and gene activity that lead to relapse, with the goal of guiding future treatments.
-
Risk factors and inflammation biomarkers for cardiovascular disease in older adults with myelodysplastic syndromes
A study focuses on older adults with myelodysplastic syndromes to understand why they have higher cardiovascular risk and how inflammatory proteins in the blood might help predict it.
-
Therapeutic targeting of transcription-epigenetic defects in SF3B1-mutant MDS
A training-focused grant to help a clinician-scientist develop therapies for adults with a common bone marrow failure condition called SF3B1-mutant myelodysplastic syndrome (MDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.